Unlock hundreds more features
Save your Quiz to the Dashboard
View and Export Results
Use AI to Create Quizzes and Analyse Results

OR
Sign inSign in with Facebook
Sign inSign in with Google
Quizzes > Quizzes for Business > Healthcare

GLP-1 Agonist Knowledge Quiz Challenge

Sharpen Your Understanding of GLP-1 Agonists

Difficulty: Moderate
Questions: 20
Learning OutcomesStudy Material
Colorful paper art illustrating a GLP-1 Agonist Knowledge Quiz theme

Welcome to the GLP-1 agonist quiz designed for healthcare professionals and students aiming to bolster their pharmacology knowledge. Joanna Weib invites you to explore essential drug mechanisms, dosing strategies, and patient considerations in this dynamic pharmacology quiz. Learners will gain confidence applying GLP-1 agonist concepts in clinical scenarios - and they can freely tailor every question in our editor. If you enjoy assessments, explore our Knowledge Assessment Quiz or sharpen digital skills with IT Fundamentals Knowledge Quiz . Want more challenges? Check out our comprehensive quizzes.

What is the primary mechanism of action of GLP-1 receptor agonists?
They mimic the endogenous GLP-1 hormone, enhancing glucose-dependent insulin secretion.
They inhibit dipeptidyl peptidase-4 (DPP-4) activity to prolong incretin action.
They stimulate glucagon release from alpha cells to increase glucose availability.
They block insulin degradation in the liver to increase circulating insulin levels.
GLP-1 receptor agonists directly bind and activate the GLP-1 receptor, promoting glucose-dependent insulin secretion and suppressing glucagon release. This mechanism distinguishes them from DPP-4 inhibitors which prevent GLP-1 breakdown.
Which effect on gastrointestinal function is characteristic of GLP-1 receptor agonists?
They accelerate gastric emptying, leading to faster nutrient absorption.
They slow gastric emptying, promoting satiety and lowering postprandial glucose.
They have no impact on gastric motility.
They increase gastrointestinal secretion of digestive enzymes.
GLP-1 agonists slow gastric emptying, which enhances early satiety and attenuates postprandial glucose spikes. This effect is key to their weight loss and glycemic benefits.
Which of the following is an example of a GLP-1 receptor agonist?
Exenatide
Sitagliptin
Insulin glargine
Metformin
Exenatide is a GLP-1 receptor agonist that mimics endogenous GLP-1 activity. Sitagliptin is a DPP-4 inhibitor, insulin glargine is a basal insulin, and metformin is a biguanide.
What is the most common route of administration for GLP-1 receptor agonists?
Subcutaneous injection
Oral tablet
Intravenous infusion
Intramuscular injection
GLP-1 receptor agonists are primarily administered by subcutaneous injection to achieve sustained absorption and avoid extensive first-pass metabolism. Oral formulations are in development but not yet common.
Which of the following is the most frequently reported side effect of GLP-1 receptor agonists?
Nausea
Hypoglycemia
Weight gain
Edema
Nausea is the most common adverse event associated with GLP-1 agonists, particularly during dose escalation. It usually diminishes over time with continued therapy.
Which GLP-1 receptor agonist formulation is typically dosed twice daily?
Exenatide immediate-release
Liraglutide
Dulaglutide
Semaglutide
Exenatide immediate-release is dosed at 5 - 10 mcg twice daily before meals. Liraglutide is once daily, while dulaglutide and semaglutide are administered weekly.
Which GLP-1 receptor agonist has the longest plasma half-life, allowing for once-weekly dosing?
Semaglutide
Exenatide immediate-release
Liraglutide
Lixisenatide
Semaglutide has a half-life of approximately one week due to its albumin binding and structural modifications, enabling once-weekly dosing. Other agonists have shorter half-lives.
In patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), which GLP-1 receptor agonist is generally contraindicated?
Exenatide
Liraglutide
Dulaglutide
Semaglutide
Exenatide is primarily renally cleared and is contraindicated in patients with an eGFR below 30 mL/min/1.73 m2. Other GLP-1 agonists are cleared by proteolysis and generally do not require adjustment.
Which patient scenario is NOT an approved indication for GLP-1 receptor agonist therapy?
A patient with type 1 diabetes mellitus
A patient with type 2 diabetes and established cardiovascular disease
A patient with type 2 diabetes inadequately controlled on metformin
A patient with obesity and pre-diabetes seeking weight loss
GLP-1 agonists are approved for type 2 diabetes and weight management but are not indicated for type 1 diabetes as they rely on endogenous insulin secretion.
Which GLP-1 receptor agonist has an FDA indication for chronic weight management at higher doses?
Semaglutide
Exenatide
Dulaglutide
Lixisenatide
Semaglutide at higher weekly doses (Wegovy®) is FDA-approved for chronic weight management. Liraglutide also has a weight indication but was not listed here.
What is the recommended starting dose for liraglutide when initiating therapy for type 2 diabetes?
0.6 mg subcutaneously once daily
0.3 mg subcutaneously once daily
1.2 mg subcutaneously once daily
2.4 mg subcutaneously once daily
When initiating liraglutide for type 2 diabetes, the dose starts at 0.6 mg daily for one week to improve tolerability, then increases to 1.2 mg daily.
A patient is started on exenatide immediate-release 5 mcg twice daily. After how long should the dose be increased to 10 mcg twice daily if tolerated?
After 1 month (4 weeks)
After 1 week
After 3 days
After 12 weeks
Exenatide immediate-release is initiated at 5 mcg twice daily for one month, then increased to 10 mcg twice daily if tolerated. This gradual titration helps minimize gastrointestinal side effects.
Which strategy is recommended for managing nausea when initiating GLP-1 receptor agonist therapy?
Slow dose titration over several weeks
Administer with high-fat meals immediately
Double the initial dose and then taper
Take only every other day
Slow dose titration is the cornerstone of managing GLP-1 - associated nausea, allowing the gastrointestinal system to adapt. Rapid dose increases often worsen side effects.
When adding a GLP-1 receptor agonist to basal insulin, what is the primary glycemic benefit?
Reduced postprandial glucose excursions
Increased risk of severe hypoglycemia
Marked weight gain
No change in overall glycemic control
Adding a GLP-1 agonist to basal insulin specifically targets postprandial glucose spikes and promotes weight neutrality or loss, while basal insulin controls fasting glucose.
Why is injection-site rotation important when using subcutaneous GLP-1 receptor agonists?
To prevent lipohypertrophy and improve drug absorption
To decrease the risk of systemic infection
To enhance first-pass hepatic metabolism
To increase the half-life of the medication
Rotating injection sites reduces the risk of lipohypertrophy, which can impair absorption and alter glycemic control. It also maintains skin integrity over time.
Which intracellular second messenger is directly increased when GLP-1 receptor agonists activate their receptor on beta cells?
Cyclic adenosine monophosphate (cAMP)
Inositol trisphosphate (IP3)
Diacylglycerol (DAG)
Cyclic guanosine monophosphate (cGMP)
GLP-1 receptor activation leads to increased intracellular cAMP via Gs protein coupling. Elevated cAMP enhances insulin granule exocytosis and beta-cell survival.
Which GLP-1 receptor agonist is least dependent on renal clearance and does not require dose adjustment in renal impairment?
Liraglutide
Exenatide
Lixisenatide
Albiglutide
Liraglutide is metabolized by proteolytic degradation and not cleared renally, so no dose adjustment is needed in renal impairment. Exenatide and lixisenatide are renally excreted.
Which cardiovascular outcome trial demonstrated a reduction in major adverse cardiovascular events (MACE) with liraglutide therapy?
LEADER
ELIXA
SUSTAIN-6
REWIND
The LEADER trial showed that liraglutide therapy significantly reduced MACE in patients with type 2 diabetes and high cardiovascular risk. Other trials studied different agents or outcomes.
A 68-year-old patient with stage 4 chronic kidney disease and frequent GI intolerance requires a GLP-1 agonist. Which agent is most appropriate?
Dulaglutide
Exenatide immediate-release
Exenatide extended-release
Lixisenatide
Dulaglutide is not renally excreted and requires no adjustment in severe CKD. Its weekly dosing and slower titration may also improve GI tolerability compared to exenatide or lixisenatide.
What is the primary rationale for combining a GLP-1 receptor agonist with an SGLT2 inhibitor in type 2 diabetes management?
Complementary mechanisms improve glycemic control and reduce cardiovascular risk.
Both agents primarily act on the same pathway to double efficacy.
Combination prevents any risk of genital mycotic infections.
It eliminates the need for insulin therapy completely.
GLP-1 agonists and SGLT2 inhibitors have complementary actions - insulinotropic and natriuretic pathways - leading to improved glycemic control, weight loss, and demonstrated cardiovascular benefits.
0
{"name":"What is the primary mechanism of action of GLP-1 receptor agonists?", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"What is the primary mechanism of action of GLP-1 receptor agonists?, Which effect on gastrointestinal function is characteristic of GLP-1 receptor agonists?, Which of the following is an example of a GLP-1 receptor agonist?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}

Learning Outcomes

  1. Identify the primary mechanism of action of GLP-1 agonists
  2. Analyse pharmacokinetic properties of common GLP-1 medications
  3. Evaluate clinical indications and patient eligibility criteria
  4. Apply dosing guidelines to real-world case scenarios
  5. Demonstrate knowledge of potential side effects and management
  6. Master strategies for optimizing treatment outcomes with GLP-1 therapy

Cheat Sheet

  1. Mechanism of action - GLP-1 agonists act like your body's own "sugar bouncer," mimicking the incretin hormone GLP-1 to boost insulin release, lower glucagon signals, and even slow down gastric emptying for smoother blood sugar rides. Ready to geek out on the science? Explore the mechanism
  2. Pharmacokinetics - Think of exenatide as the sprinter (3 - 4 hour half-life) and dulaglutide as the marathoner (4.7 - 5.5 day half-life). These timing differences shape how often you inject and help tailor treatment to your lifestyle. Dive into pharmacokinetics
  3. Clinical indications - GLP-1 agonists are champions in type 2 diabetes management and also score bonus points for aiding weight loss in obesity. They're FDA-approved for both - so they wear two hats in your treatment toolkit. Discover clinical uses
  4. Patient eligibility - If everyday diabetes meds are leaving you high and dry or if shedding pounds feels impossible, GLP-1 agonists might be your new best friend. They're tailored for T2DM patients struggling to hit A1C goals and folks tackling obesity. Check eligibility criteria
  5. Dosing guidelines - Your injection schedule depends on the agent: some (like liraglutide) need daily check-ins, while others (semaglutide) prefer a weekly hangout. Always stick to the official prescribing guide to nail your timing. Review dosing guidelines
  6. Common side effects - Most people meet GLP-1 agonists with a bit of tummy rebellion - nausea, vomiting, or diarrhea. Luckily, these GI gremlins often pack up and leave as your body adjusts. Browse common side effects
  7. Serious rare side effects - Though uncommon, acute pancreatitis and gallbladder troubles have turned up in GLP-1 storylines. Keep an eye out for warning signs and hit pause on treatment if they appear. Understand rare risks
  8. Contraindications - GLP-1 agonists come with their own "do not enter" list: steer clear if there's a history of medullary thyroid carcinoma or MEN 2 syndrome. Safety first is the golden rule here. View contraindications
  9. Beyond glycemic control - These agents are multitasking rock stars - helping with weight loss, lowering blood pressure, and even giving your lipid profile a friendly nudge. It's like a health spa for your metabolic system! Learn about added benefits
  10. Treatment optimization - Start low, go slow: ease into the smallest effective dose, then up the ante bit by bit to dodge unwanted side effects. Couple this smart titration with diet and exercise for a powerhouse combo. See optimization tips
Make a Quiz (FREE) Copy & Edit This Quiz Create a Quiz with AI

Healthcare Quizzes

Powered by: Quiz Maker